AACR20: RWE supports the use of adjuvant immunotherapy in Stage III melanoma patients

Written by Caitlin Killen, Future Science group

Research presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II (22–24 June 2020) has demonstrated that Stage III melanoma patients who receive adjuvant immunotherapy have an improved survival benefit compared to patients who did not receive immunotherapy following surgery. Researchers from Loma Linda University (CA, USA) analyzed data from the National Cancer Database (NCDB) to investigate treatment data from patients diagnosed between 2015–2016 and survival data from individuals diagnosed in 2015. The NCDB is a clinical oncology database that includes 72% of newly diagnosed cases in the USA. The data of Stage III melanoma patients who...

To view this content, please register now for access

It's completely free